Skip to main content
. Author manuscript; available in PMC: 2009 Jun 2.
Published in final edited form as: J Pharmacol Exp Ther. 2008 Mar 25;325(3):751–757. doi: 10.1124/jpet.108.136374

Table 1.

Mean arterial pressure (mmHg) during basal, treatment, and recovery periods from each group

Basal Treatment Recovery
CAP 119 ± 6 118 ± 7 118 ± 6
CAPZ+CAP 125 ± 2 125 ± 2 124 ± 2
RP67580+CAP 124 ± 3 124 ± 2 121 ± 2
L703, 606+CAP 121 ± 6 122 ± 5 125 ± 5
CGRP8-37+CAP 124 ± 3 122 ± 3 120 ± 4
SP 121 ± 5 120 ± 5 118 ± 4
CAPZ+SP 120 ± 4 120 ± 3 119 ± 4
CGRP 117 ± 5 118 ± 6 118 ± 5
CAPZ+CGRP 120 ± 4 123 ± 4 120 ± 4

Value was expressed as mean ± SE, n=5–7 in each group

CAP, Capsaicin   CAPZ, Capsazepine, TRPV1 antagonist

RP67580, NK1 antagonist   L703,606, NK1 antagonist

CGRP8-37, CGRP receptors antagonist   SP, Substance P

CGRP, Calcitonin gene-related peptide